ArticleNature communications2023
Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance crisis: could artificial intelligence be the solution?Military Medical Research · 2024Pooled it
- A cell-free system for 1,6-hexanediamine synthesis using bulk chemical caprolactam as the feedstock.Synthetic and systems biotechnology · 2026Article
- Enhancing the Secretion Systems: Genetic Engineering of Super Bioagents for Effective Plant Disease Control.Biotechnology and bioengineering · 2026Review
- Protocol for tri-modal pretraining and downstream fine-tuning of protein representations using ProteinAligner.STAR protocols · 2026Article
- Selective α-Amylase Inhibition by Plant Defensins: Structural Determinants, Engineering Strategies, and Translational Prospects.Probiotics and antimicrobial proteins · 2026Review
- Antibiotic-Free Strategies for Managing Antimicrobial-Resistant Infections.Pharmaceutics · 2026Review
- A unified framework for potency-oriented AMP discovery via multi-modal learning and guided sequence synthesis.PLoS computational biology · 2026Article
- Anticancer Potential of Antimicrobial Peptides: Mechanisms, Clinical Application, Challenges, and Future Prospects.Drug development research · 2026Review
- Artificial Intelligence-Driven Antimicrobial Peptide Discovery: Prediction, Generation, Mining and Optimization.Probiotics and antimicrobial proteins · 2026Review
- Structural Remodeling of TCR-HLA-DQ8 Recognition by a β-Cell Stress-Associated C19S Insulin Neoepitope in Type 1 Diabetes.International journal of molecular sciences · 2026Article
- Antimicrobial peptides in anti-infective and immunomodulatory applications: Mechanisms, challenges, and emerging computational design.Zoological research · 2026Review
- Generative AI for controllable protein sequence design: A survey.npj drug discovery · 2026Review
- A Comprehensive Review of Antimicrobial Peptides and Smart Biomaterials in Chronic Wound Therapy: Overcoming Biofilms, Resistance, and Translational Barriers.International journal of molecular sciences · 2026Review
- Harnessing generative AI for predicting and optimizing antimicrobial peptides against drug-resistant infections.npj antimicrobials and resistance · 2026Article
- A tri-modal contrastive learning framework for protein representation learning.Cell reports methods · 2026Article
- Generative models for antimicrobial peptide design: auto-encoders and beyond.BioData mining · 2026Article
- MAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary-physicochemical analysis.Briefings in bioinformatics · 2026Article
- De Novo Multi-Mechanism Antimicrobial Peptide Design via Multimodal Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Design-driven optimization of low-cost reagent formulations for reproducible and high-yielding cell-free gene expression.Nature communications · 2026Article
- The rise and future of peptide-based antimicrobials.Journal of microbiology (Seoul, Korea) · 2026Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioactive peptides are key molecules in health and medicine. Deep learning holds a big promise for the discovery and design of bioactive peptides. Yet, suitable experimental approaches are required to validate candidates in high throughput and at low cost. Here, we established a cell-free protein synthesis (CFPS) pipeline for the rapid and inexpensive production of antimicrobial peptides (AMPs) directly from DNA templates. To validate our platform, we used deep learning to design thousands of AMPs de novo. Using computational methods, we prioritized 500 candidates that we produced and screened with our CFPS pipeline. We identified 30 functional AMPs, which we characterized further through molecular dynamics simulations, antimicrobial activity and toxicity. Notably, six de novo-AMPs feature broad-spectrum activity against multidrug-resistant pathogens and do not develop bacterial resistance. Our work demonstrates the potential of CFPS for high throughput and low-cost production and testing of bioactive peptides within less than 24 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.